Gardasil® 9 (human papillomavirus 9-valent vaccine, recombinant) – Expanded indication
June 12, 2020 - Merck announced the FDA approval of Gardasil 9 (human papillomavirus [HPV] 9-valent vaccine, recombinant), for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58 in males and females 9 through 45 years of age.
Top